ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback